MedTrace Logo

Comparative Study of microRNA Changes in Patients With Reactive Lymphoid Hyperplasia and Malignant Lymphoma

NCT03167476 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2017-05-30

No results posted yet for this study

Summary

The objectives are to:

1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma.
2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects.
3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia.

The objectives are to:

1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma.
2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects.
3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia.

This trial involves tissue samples diagnosed as lymphoma and reactive hyperplasia. The investigators will develop panels of miRNAs that are specific biomarkers of lymphoma, and assist clinical outcomes with these miRNAs.

Conditions

  • Lymphoma
  • Hyperplasia Lymphoid Reactive

Sponsors & Collaborators

  • Chengdu Nuoen Biotechnologies, Inc.

    collaborator OTHER

  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER

  • University of Electronic Science and Technology of China

    lead OTHER

Principal Investigators

  • Jian Huang, PhD · University of Electronic Science and Technology of China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2017-12-01
Completion
2018-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03167476 on ClinicalTrials.gov